Myelodysplastic Syndrome Clinical Trial

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Summary

This is a Phase 2, two-stage study of the safety and efficacy of pracinostat in combination with azacitidine in patients with IPSS-R high and very high risk myelodysplastic syndrome (MDS) who are previously untreated with hypomethylating agents (HMAs). Enrollment in this study will be limited to high/very high risk MDS because this group represents the highest unmet need, with median survival of less than 18 months.

Stage 1a will be conducted as an open-label single arm in up to 40 subjects to assess if this regimen with a lower pracinostat dose results in a discontinuation rate that meets a predefined threshold and in efficacy that justifies expansion of enrollment into Stage 1b.

A discontinuation rate of approximately ≤10% in Stage 1a, a rate comparable to that observed with azacitidine alone in study MEI-003 (NCT01873703), supports expansion into Stage 1b.

Stage 1b will be conducted as expansion of stage 1a. Approximately 20 additional subjects will be enrolled. Study drugs should be continued until disease progression or intolerable toxicity. It is important to note that the median time to achieving a response with azacitidine alone is 4 to 5 months. Furthermore, the median time to achieving a Complete Response (CR) in study MEI-003 (NCT01873703) was 4 cycles. Therefore, early (<6 months) discontinuation of trial therapy for 'no response' should be avoided. The Medical Monitor should be contacted prior to discontinuing a subject from the study to discuss the rationale for discontinuation.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Female or male subjects ≥18 years-of-age.

Histologically or cytologically documented diagnosis of MDS according to the World Health Organization (WHO) classification (Vardiman 2009, Arber 2016) with >5% and <20% bone marrow blasts by morphology and a peripheral white blood cell (WBC) count of <20,000/μL

If WBC ≥20,000/μL, cytoreduction with hydroxyurea is permitted prior to enrollment.
chronic myelomonocytic leukemia CMML-1 and CMML-2 subtypes
Classified as high or very high risk according to the Revised International Prognostic Scoring System (IPSS-R) risk category. CMML-1 and CMML-2 subtypes will be considered high-risk MDS and will not require IPSS-r scoring
Bone marrow biopsy (BMBx) and/or aspirate within 28 days prior to first study treatment.
Clinical indication for treatment with azacitidine.

Previously untreated with HMAs (prior therapy with transfusions, hematopoietic growth factors, or immunosuppressive therapy is allowed).

a. subjects who require the start of an HMA (e.g., azacitidine) due to progressing MDS may receive up to 1 cycle of azacitidine within 30 days prior to planned first dose (Cycle 1 Day 1)

Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

Adequate organ function as evidenced by:

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × the upper limit of normal (ULN).
Total bilirubin ≤1.5 × ULN or total bilirubin of ≤2 mg/dL, whichever is higher. Total bilirubin < 3 x ULN for patients with Gilbert-Meulengracht Syndrome
Serum creatinine <1.5 mg/dL, or creatinine clearance>40 mL/min.
QTcF interval ≤450 msec using the mean of triplicate electrocardiograms (ECGs).

Female subjects of childbearing potential and male subjects with female partners of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 30 days following last dose. Female subjects of childbearing potential must not be breastfeeding, or planning to breastfeed, and must have a negative pregnancy test ≤7 days before first study drug administration.

Male subjects must also refrain from donating sperm during their participation in the study.

Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
Have the willingness and ability to understand the nature of this study and to comply with the study and follow-up procedures.

Exclusion Criteria:

Bone marrow blasts ≥20%, indicating a diagnosis of acute myeloid leukemia (AML).

Received any of the following within the specified time frame prior to administration of study medication:

Any investigational agent within 14 days or 5 half-lives prior to enrollment, whichever is longer.
Hydroxyurea within 48 hours prior to first day of study treatment.
Hematopoietic growth factors: erythropoietin, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), or thrombopoietin receptor agonists at least 7 days (14 days for Aranesp), prior to study enrollment.
Major surgery within 28 days prior to first study treatment.
Subjects who have not recovered from side effects of previous therapy.

Cardiopulmonary function criteria:

Current unstable arrhythmia requiring treatment.
History of symptomatic congestive heart failure (New York Heart Association [NYHA] Class III or IV).
History of myocardial infarction, pulmonary embolism or cerebrovascular accident within 6 months of enrollment.
Current unstable angina.
Prior treatment for MDS with histone deacetylase (HDAC) inhibitors Zolinza (vorinostat), Belenodaq (belinostat), Farydak (panobinostat), Istodax (romidepsin/depsipetide), or investigational agent with significant action as an HDAC inhibitor.
Clinical evidence of central nervous system involvement.
Subjects with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis).
Uncontrolled infection with human immunodeficiency virus (HIV) or chronic hepatitis B or C.
Life-threatening illness unrelated to cancer or any serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with participation in this study.
Presence of a malignant disease within the last 12 months, with the exception of adequately treated in-situ carcinomas, basal or squamous cell carcinoma, non-melanomatous skin cancer, or malignancies treated with curative intent and no evidence of active disease in prior 12 months and felt to be low risk for recurrence. Other malignancies may be considered after consultation with the Medical Monitor
An unwillingness or inability (including breastfeeding women, prohibited concomitant medications, uncontrolled infections, psychological, familial, sociological, or geographical conditions) to comply with study and/or follow-up procedures as outlined in the protocol
Known hypersensitivity to any components of pracinostat, azacitidine or mannitol
Current smoking or vaporizing of tobacco or cannabis-related products (use of patches, chewing tobacco, or nicotine gum is permitted). Subjects who stopped smoking at least 8 days prior to first pracinostat dosing can be, provided they refrain from smoking during the whole study.

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

64

Study ID:

NCT03151304

Recruitment Status:

Terminated

Sponsor:

Helsinn Healthcare SA

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 24 Locations for this study

See Locations Near You

City of Hope
Duarte California, 91010, United States
Scripps Cancer Center-Mercy
San Diego California, 92103, United States
Georgia Cancer Center at Augusta University
Augusta Georgia, 30912, United States
georgia cancer Center
Augusta Georgia, 30912, United States
Pontchartrain cancer Center
Covington Louisiana, 70433, United States
RCCA MD LLC (The Center for Cancer and Blood Disorders)
Bethesda Maryland, 20817, United States
Michigan Center of Medical Research
Farmington Hills Michigan, 48334, United States
Michigan State University, Breslin Cancer Center
Lansing Michigan, 48910, United States
university of minnesota medical Center, Fairview
Minneapolis Minnesota, 55455, United States
Mercy Medical Research Institute
Springfield Missouri, 65807, United States
New Mexico Cancer care Alliance
Albuquerque New Mexico, 87131, United States
University of Rochester Medical Center
Rochester New York, 14642, United States
Stony Brook University
Stony Brook New York, 11794, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Southeastern Medical Oncology Center
Goldsboro North Carolina, 27534, United States
Oncology Hematology Care
Cincinnati Ohio, 45242, United States
University Hospitals Cleveland Medical Center
Cleveland Ohio, 44106, United States
Cancer Centers of Southwest Oklahoma
Lawton Oklahoma, 73501, United States
Oklahoma Cancer Specialists and Research Institute
Tulsa Oklahoma, 74146, United States
Providence Portland Medical center
Portland Oregon, 97213, United States
UT Southwestern Medical Center
Dallas Texas, 75390, United States
UVA Health System Division of Hematology & Oncology
Charlottesville Virginia, 22908, United States
Swedish Cancer Institute
Seattle Washington, 98104, United States
Universityof Wisconsin Clinical Science Center
Madison Wisconsin, 53792, United States
Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

64

Study ID:

NCT03151304

Recruitment Status:

Terminated

Sponsor:


Helsinn Healthcare SA

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider